Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bacteriophage Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults

NCT02757755
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AB-SA01 (10^8 PFU per phage), AB-SA01 (10^9 PFU per phage), Placebo (for Cohort 10^8), Placebo (for Cohort 10^9)
Biological
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Sep 23, 2026, 2:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Terpenoid- and Carotenoid-modifying Enzymes in the Human Gut

NCT07589166
View directory record Official record
Conditions
Terpene Synthases, Carotenoid Modifying Enzymes
Interventions
No Intervention: Observational Cohort
Other
Lead sponsor
North Carolina State University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 23, 2026, 2:19 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients

NCT06409819
View directory record Official record
Conditions
Urinary Tract Infection, Recurrent
Interventions
phage therapy, control
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 23, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional

Project 4: ACHIEVE PATHFINDER

NCT06070428
View directory record Official record
Conditions
Heart Failure
Interventions
PAC provision at hospital discharge, Control non-intervention; PAC without filter
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 23, 2026, 2:19 PM EDT
Not yet recruiting Phase 1 Interventional

Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis

NCT06750588
View directory record Official record
Conditions
Alcohol-Associated Hepatitis
Interventions
bacteriophage preparation
Drug
Lead sponsor
Nterica Bio inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant

NCT00089180
View directory record Official record
Conditions
Actinic Keratosis, Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Interventions
liposomal T4N5 lotion, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects

NCT05166096
View directory record Official record
Conditions
Healthy
Interventions
Rho-11, aspirin 325mg
Drug
Lead sponsor
Rhoshan Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

NCT05277350
View directory record Official record
Conditions
E.Coli Infections, Bloodstream Infection
Interventions
SNIPR001, Placebo
Drug
Lead sponsor
SNIPR Biome Aps.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 23, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional

Cognitive Rehabilitation for Survivors of Childhood Medulloblastoma Using Real Time Hemodynamic Neurofeedback

NCT07830134
View directory record Official record
Conditions
Medulloblastoma, Childhood, Survivorship
Interventions
rt fMRI Neurofeedback (DLPFC), rt fMRI Neurofeedback (PAC)
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
10 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

NCT04596319
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection, Lung Infection Pseudomonal
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Los Angeles, California • Tampa, Florida • Boise, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Slippers to Reduce Transfer From Floors to Surfaces

NCT04935892
View directory record Official record
Conditions
Transmission, Other/Miscellaneous
Interventions
Slippers
Behavioral
Lead sponsor
Louis Stokes VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 23, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional

Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

NCT02925533
View directory record Official record
Conditions
Bladder Cancer
Interventions
B-701, Pembrolizumab
Drug
Lead sponsor
Mark Pomerantz, MD
Other
Eligibility
18 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

NCT05453578
View directory record Official record
Conditions
Bacterial Disease Carrier, Cystic Fibrosis
Interventions
Placebo, WRAIR-PAM-CF1
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 23, 2026, 2:19 PM EDT
Enrolling by invitation No phase listed Observational

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

NCT06262282
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary
Interventions
mycobacteriophage
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 23, 2026, 2:19 PM EDT
Recruiting No phase listed Observational

Biomarkers of Phage Treatment Response in NTM and Other Infections

NCT07076238
View directory record Official record
Conditions
Nontuberculous Mycobacterial Lung Disease
Interventions
Bacteriophage Treatment
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 23, 2026, 2:19 PM EDT
Suspended Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects

NCT05715619
View directory record Official record
Conditions
Vancomycin-Resistant Enterococcal Colonization
Interventions
VRELysin™, Placebo
Biological · Other
Lead sponsor
Intralytix, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome

NCT00001145
View directory record Official record
Conditions
Immunoproliferative Disorder
Interventions
Bacteriophage, rhuCD40L, KLH
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 23, 2026, 2:19 PM EDT
Recruiting Phase 1 Interventional

Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection

NCT07275905
View directory record Official record
Conditions
Cystic Fibrosis (CF), Achromobacter Infection
Interventions
AchromoPhage
Biological
Lead sponsor
Ghady Haidar
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
San Diego, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional

Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

NCT05010577
View directory record Official record
Conditions
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis
Interventions
BX004-A, Placebo
Drug
Lead sponsor
BiomX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 23, 2026, 2:19 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)

NCT01617122
View directory record Official record
Conditions
Primary Immune Deficiency Diseases
Interventions
Bacteriophage OX174
Biological
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Sep 23, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional

Multiomic Diagnostics in Youth With Psychosis

NCT05457140
View directory record Official record
Conditions
Psychosis
Interventions
Genetic: Genomic sequencing and molecular diagnostic results, if any., Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)
Genetic · Diagnostic Test
Lead sponsor
Rady Pediatric Genomics & Systems Medicine Institute
Other
Eligibility
7 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 23, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

NCT00006066
View directory record Official record
Conditions
HIV Infections
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Diphtheria and Tetanus Toxoids Adsorbed, Tetanus and Diphtheria Toxoids Adsorbed, Bacteriophage phi X 174, Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 23, 2026, 2:19 PM EDT
Recruiting Phase 2 Interventional

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

NCT05488340
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX
Drug
Lead sponsor
Locus Biosciences
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Fresno, California • Lancaster, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 2:19 PM EDT